New anti-epileptic drugs: Overcoming the limits of randomised controlled trials

International Journal of Evidence-Based Healthcare

Volumn 9, Issue 4, 2011, Pages 440-443

  Brigo, Francesco ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Anti epileptic drug; Focal epilepsy; Multiple treatment meta analysis; Placebo; Randomised controlled trial

Indexed keywords

ANTICONVULSIVE AGENT; PLACEBO;

EVIDENCE BASED MEDICINE; FOCAL EPILEPSY; HUMAN; META ANALYSIS; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTICONVULSANTS; EPILEPSIES, PARTIAL; EVIDENCE-BASED MEDICINE; HUMANS; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84858770622     PISSN: 17441595     EISSN: 17441609     Source Type: Journal    
DOI: 10.1111/j.1744-1609.2011.00236.x     Document Type: Note

References (15)

1. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol 2011; 64: 163-71.
2. Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med 2008; 148: 544-53.
3. Otoul C, Arrigo C, van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other secondgeneration antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005; 28: 72-8.
4. Wolinsky H. The battle of Helsinki: two troublesome paragraphs in the Declaration of Helsinki are causing a furore over medical research ethics. EMBO Rep 2006; 7: 670-2.
5. French JA, Kryscio RJ. Active control trials for epilepsy: avoiding bias in head-to-head trials. Neurology 2006; 66: 1294-5.
6. Marson AG, Williamson PR. Interpreting regulatory trials in epilepsy. Curr Opin Neurol 2009; 22: 167-73.
7. Gamble C, Williamson PR, Chadwick DW, Marson AG. A metaanalysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006; 66: 1310-17.
8. Marson AG, Al-Kharusi AM, Alwaidh M et al.; SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369: 1000-15.
9. Panayiotopoulos CP. A Clinical Guide to Epileptic Syndromes and Their Treatment, 2nd edn. London: Springer-Verlag, 2007.
10. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17: 279-301.
11. Marson AG, Hutton JL, Leach JP et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 2001; 46: 259-70.
12. Tudur Smith C, Marson AG, Chadwick DW, Williamson PR. Multiple treatment comparisons in epilepsy monotherapy trials. Trials 2007; 8 doi: 10.1186/1745-6215-8-34.
13. French JA, Wang S, Warnock B, Temkin N. Historical control monotherapy design in the treatment of epilepsy. Epilepsia 2010; 51: 1936-43.
14. Perucca E. When clinical trials make history: demonstrating efficacy of new antiepileptic drugs as monotherapy. Epilepsia 2010; 51: 1933-5.
15. Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47: 1094-120.